Brooks Laboratories Limited (BROOKS) AI Stock Analysis

• Market Cap: ₹3.12B
• Dividend Yield: N/A
• Average Volume (3M): 3.41K
• Price to Earnings (P/E): 22.6
• Beta (1Y): 1.18
• Revenue Growth: 18.67%
• EPS Growth: N/A
• Country: IN
• Employees: 293
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 2.71
• Shares Outstanding: 29,457,249
• 10 Day Avg. Volume: 3,473
• 30 Day Avg. Volume: 3,414
• PEG Ratio: 0.59
• Price to Book (P/B): 3.42
• Price to Sales (P/S): 4.06
• P/FCF Ratio: -3.45K
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: ₹116.00 ▼(-6.19% Downside)

Brooks Laboratories Limited's overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. The high P/E ratio suggests overvaluation, further weighing down the score. The absence of earnings call insights and corporate events leaves the focus on existing financial and technical challenges.

Positive Factors

Debt Management

Improved debt management enhances financial stability and reduces risk, supporting long-term operational flexibility and investment capacity.

Service Model

The fee-for-service model provides a stable revenue stream and aligns with industry needs, supporting consistent cash flow and market positioning.

Margin Improvement

Improved margins indicate better cost management and operational efficiency, which can enhance profitability and competitive positioning over time.

Negative Factors

Negative Cash Flow

Sustained negative cash flow suggests liquidity challenges, potentially limiting the company's ability to invest in growth and manage debt obligations.

Revenue Volatility

Revenue volatility can hinder long-term planning and investment, impacting the company's ability to sustain growth and market competitiveness.

Negative Net Income

Ongoing net losses undermine financial health and investor confidence, posing risks to long-term sustainability and strategic initiatives.

Brooks Laboratories Limited Business Overview & Revenue Model

Company Description

Brooks Laboratories Limited (BROOKS) is a leading provider of laboratory services, specializing in the development, manufacture, and commercialization of analytical testing solutions for various industries, including pharmaceuticals, biotechnology, and life sciences. The company is dedicated to ensuring product quality and compliance with regulatory standards, offering a range of services such as stability testing, method development, and validation. With a focus on innovation and customer-centric solutions, BROOKS aims to support its clients throughout the product lifecycle, delivering reliable and efficient laboratory services.

How the Company Makes Money

Brooks Laboratories Limited generates revenue primarily through its laboratory services, which include analytical testing and consulting for pharmaceutical and biotech companies. The company operates on a fee-for-service model, charging clients based on the specific services rendered, such as stability testing or method validation. Key revenue streams include long-term contracts with pharmaceutical companies for ongoing testing services, one-time project fees for specific studies, and partnerships with research institutions for collaborative projects. Additionally, BROOKS may benefit from strategic alliances with other companies in the industry, enabling access to new markets and enhancing its service offerings, ultimately contributing to its overall earnings.

Brooks Laboratories Limited Financial Statement Overview

Summary

Brooks Laboratories Limited faces challenges with financial stability and profitability, as evidenced by negative net income and cash flow issues. Despite some improvements in margins and debt management, revenue volatility and inconsistent cash flow remain significant concerns.

Income Statement

Brooks Laboratories Limited has shown inconsistent revenue growth, with a noticeable decline in revenue from 2022 to 2023, followed by a recovery in 2025. Gross profit margins have been volatile, indicating instability in cost management. However, the company has managed to improve its EBIT and EBITDA margins in 2025 compared to previous years, although net profit margins remain negative due to persistent net losses.

Balance Sheet

The company's debt-to-equity ratio has improved as total debt decreased over recent years, suggesting better leverage management. The return on equity remains negative due to ongoing net losses, which is a concern. However, the equity ratio is relatively stable, indicating a strong equity position relative to total assets.

Cash Flow

Cash flow from operations has been negative for several years, but there has been some improvement in 2025. The company has struggled with free cash flow, indicating potential liquidity issues. The operating cash flow to net income ratio remains unfavorable due to sustained losses, although free cash flow has shown slight growth from a very low base.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.08B	825.57M	794.86M	624.80M	911.85M	770.68M
Gross Profit	343.34M	139.22M	225.13M	126.02M	-79.11M	218.28M
EBITDA	59.11M	58.22M	41.73M	-291.68M	-134.50M	12.52M
Net Income	-4.08M	-99.67M	-195.92M	-209.00M	-193.13M	-193.75M
Balance Sheet
Total Assets	0.00	1.24B	904.45M	1.10B	1.96B	1.62B
Cash, Cash Equivalents and Short-Term Investments	12.48M	12.48M	1.25M	232.00K	26.05M	8.84M
Total Debt	0.00	75.83M	56.42M	65.12M	252.59M	313.85M
Total Liabilities	-981.04M	255.90M	248.60M	356.44M	615.91M	829.29M
Stockholders Equity	981.04M	981.04M	655.85M	739.53M	874.90M	791.48M
Cash Flow
Free Cash Flow	0.00	-971.00K	-101.20M	-149.58M	-650.53M	-11.55M
Operating Cash Flow	0.00	17.62M	-96.81M	-144.91M	-374.41M	44.59M
Investing Cash Flow	0.00	-460.41M	1.82M	4.95M	-249.09M	-51.30M
Financing Cash Flow	0.00	441.96M	96.01M	114.14M	640.71M	11.59M

Brooks Laboratories Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 123.65
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BROOKS, the sentiment is Negative. The current price of 123.65 is above the 20-day moving average (MA) of 105.03, above the 50-day MA of 119.82, and below the 200-day MA of 132.27, indicating a bearish trend. The MACD of -4.56 indicates Negative momentum. The RSI at 42.51 is Neutral, neither overbought nor oversold. The STOCH value of 65.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BROOKS.

Brooks Laboratories Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MEDICO	76 Outperform	₹4.15B	36.60	―	―	21.55%	47.80%
MEDICAMEQ	65 Neutral	₹5.59B	50.25	―	0.24%	-9.16%	49.09%
ZIMLAB	63 Neutral	₹3.47B	52.70	―	―	-5.82%	-59.22%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALBERTDAVD	51 Neutral	₹4.53B	―	―	0.63%	-13.51%	-122.00%
NECLIFE	50 Neutral	₹3.18B	-1.77	―	―	-30.27%	-3470.06%
BROOKS	41 Neutral	₹3.12B	22.58	―	―	18.67%	―

Brooks Laboratories Limited Corporate Events

Brooks Laboratories Announces Strategic Merger of Joint Venture

Brooks Laboratories Limited has announced a merger by absorption involving its joint venture, Brooks Steriscience Limited, and several other entities. This Composite Scheme of Arrangement and Amalgamation aims to streamline operations and enhance strategic positioning. The merger is subject to approvals from shareholders, creditors, and various regulatory authorities, including SEBI and the National Company Law Tribunal, which could significantly impact the company’s operational efficiency and market presence.